Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes

被引:17
作者
Atmaca, Aysegul [1 ]
Gedik, Olcay [1 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Endocrinol & Metab, Ankara, Turkey
关键词
diabetic nephropathy; microalbuminuria; ACE inhibitors; ATII receptor blockers; renoprotection;
D O I
10.1007/BF02850049
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The goal of this study was to compare the effects of lisinopril, losartan, and their combination on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Patients were randomly assigned to 3 groups: group I (n=9), group 2 (n=9), and group 3 (n=8) received 10 mg lisinopril, 50 mg losartan, and 10 mg lisinopril plus 50 mg losartan, respectively, each day. For 12 mo, the 24-h urine albumin excretion rate was assessed at 3-mo intervals. At study completion, the urine albumin excretion rate had been reduced significantly in each group (P=.001); however, no significant differences were noted among groups (P=.587). Investigators in the present study have concluded that lisinopril, losartan, and their combination have similar effects on microalbuminuria in normotensive patients with type 2 diabetes mellitus, and that combination therapy does not provide additional benefit.
引用
收藏
页码:615 / 622
页数:8
相关论文
共 50 条
  • [1] Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes
    Aysegul Atmaca
    Olcay Gedik
    Advances in Therapy, 2006, 23 : 615 - 622
  • [2] Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus
    Hughes, DB
    Britton, ML
    PHARMACOTHERAPY, 2005, 25 (11): : 1602 - 1620
  • [3] Cost-effectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria
    Sakthong, P
    Tangphao, O
    Eiam-Ong, S
    Kamolratanakul, P
    Supakankunti, S
    Himathongkam, T
    Yathavong, K
    NEPHROLOGY, 2001, 6 (02) : 71 - 77
  • [4] Effects of Spironolactone in Combination with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Proteinuria
    Kim, Ha Yeon
    Bae, Eun Hui
    Ma, Seong Kwon
    Kim, Soo Wan
    KIDNEY & BLOOD PRESSURE RESEARCH, 2014, 39 (06) : 573 - 580
  • [5] Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease
    Kolesnyk, I.
    Struijk, D. G.
    Dekker, F. W.
    Krediet, R. T.
    NETHERLANDS JOURNAL OF MEDICINE, 2010, 68 (01) : 15 - 23
  • [6] Are angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers teratogenic?
    Morton, A. P.
    DIABETIC MEDICINE, 2013, 30 (10) : 1263 - 1264
  • [7] The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors
    Sica, DA
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, 3 (02) : 66 - 71
  • [8] Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
    Liu, Chia-Lin
    Shau, Wen-Yi
    Chang, Chia-Hsuin
    Wu, Chi-Shin
    Lai, Mei-Shu
    JOURNAL OF EPIDEMIOLOGY, 2013, 23 (05) : 344 - 350
  • [9] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Holloway-Kew, Kara L.
    Betson, Amelia G.
    Anderson, Kara B.
    Sepetavc, Filip
    Gaston, James
    Kotowicz, Mark A.
    Liao, Wan-Hui
    Henneberg, Maciej
    Pasco, Julie A.
    CALCIFIED TISSUE INTERNATIONAL, 2022, 111 (04) : 396 - 408
  • [10] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for the Prevention of Migraines
    Gales, Barry J.
    Bailey, Emilee K.
    Reed, Ashley N.
    Gales, Mark A.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 360 - 366